{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:31:39Z","timestamp":1791909099583,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["7R01CA269223"],"award-info":[{"award-number":["7R01CA269223"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023082","name":"State of Washington","doi-asserted-by":"publisher","award":["171"],"award-info":[{"award-number":["171"]}],"id":[{"id":"10.13039\/100023082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dmd.2025.100122","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:44:09Z","timestamp":1752680649000},"page":"100122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibitory effects of \u03948-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition"],"prefix":"10.1016","volume":"53","author":[{"given":"Mengqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-9298","authenticated-orcid":false,"given":"Shelby","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keti","family":"Bardhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"issue":"25","key":"10.1016\/j.dmd.2025.100122_bib2","first-page":"597","article-title":"Prevalence of cannabis use around the world: a systematic review and meta-analysis, 2000-2024","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly"},{"issue":"12","key":"10.1016\/j.dmd.2025.100122_bib3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/17512433.2022.2148655","article-title":"Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy","volume":"15","author":"Bardhi","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42238-021-00115-8","article-title":"Delta-8-THC: delta-9-THC's nicer younger sibling?","volume":"4","author":"Kruger","year":"2022","journal-title":"J Cannabis Res"},{"key":"10.1016\/j.dmd.2025.100122_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103557","article-title":"Public interest in \u0394(8)-tetrahydrocannabinol (delta-8-THC) increased in US states that restricted \u0394(9)-tetrahydrocannabinol (delta-9-THC) use","volume":"101","author":"Leas","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.dmd.2025.100122_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfca.2020.103800","article-title":"A survey of cannabinoids and toxic elements in hemp-derived products from the United States marketplace","volume":"97","author":"Dubrow","year":"2021","journal-title":"J Food Compost Anal"},{"issue":"5","key":"10.1016\/j.dmd.2025.100122_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/can.2021.0097","article-title":"Delta(8)-THC: legal status, widespread availability, and safety concerns","volume":"6","author":"Babalonis","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"issue":"10","key":"10.1016\/j.dmd.2025.100122_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2024.0865","article-title":"Adolescent Delta8-THC and marijuana use in the US","volume":"331","author":"Harlow","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.dmd.2025.100122_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jama.2024.0801","article-title":"The public health challenge of Delta8-THC and derived psychoactive cannabis products","volume":"331","author":"Whitehill","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.dmd.2025.100122_bib10","first-page":"263","article-title":"Basic review of the cytochrome P450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100122_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/0113892002300657240521094732","article-title":"Drug-drug interaction potential of remimazolam: CYP 450, transporters, and protein binding","volume":"25","author":"Petersen","year":"2024","journal-title":"Curr Drug Metab"},{"issue":"Pt 1","key":"10.1016\/j.dmd.2025.100122_bib12","doi-asserted-by":"crossref","first-page":"116569","DOI":"10.1016\/j.bcp.2024.116569","article-title":"Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline","volume":"230","author":"Ponraj","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100122_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100122_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/jm9902281","article-title":"QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency","volume":"43","author":"Keimowitz","year":"2000","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2004.11.055","article-title":"LC-MS method for the estimation of delta8-THC and 11-nor-delta8-THC-9-COOH in plasma","volume":"38","author":"Valiveti","year":"2005","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.dmd.2025.100122_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0090-9556(25)06140-9","article-title":"Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice","volume":"9","author":"Watanabe","year":"1981","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100122_bib19","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.dmd.2025.100104","article-title":"Identification of human hepatic UDP-glucuronosyltransferases involved in the glucuronidation of temazepam","volume":"53","author":"Bardhi","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100122_bib20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100122_bib21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0090-9556(24)15224-5","article-title":"Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine","volume":"27","author":"Abdel-Rahman","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100122_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00008571-199810000-00002","article-title":"Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver","volume":"8","author":"Yang","year":"1998","journal-title":"Pharmacogenetics"},{"issue":"6","key":"10.1016\/j.dmd.2025.100122_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/tx00036a015","article-title":"Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone","volume":"6","author":"Carriere","year":"1993","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100122_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2125.1993.tb00410.x","article-title":"Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism","volume":"36","author":"Andersson","year":"1993","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100122_bib25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11095-008-9535-1","article-title":"Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes","volume":"25","author":"Coles","year":"2008","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.dmd.2025.100122_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0006-2952(99)00167-7","article-title":"Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways","volume":"58","author":"Bort","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100122_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1872312811206030002","article-title":"Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins","volume":"6","author":"Kim","year":"2012","journal-title":"Drug Metab Lett"},{"issue":"9","key":"10.1016\/j.dmd.2025.100122_bib28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0090-9556(25)07487-2","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100122_bib29","series-title":"M12 Drug Interaction Studies","first-page":"50","year":"2024"},{"key":"10.1016\/j.dmd.2025.100122_bib30","series-title":"Quantification of the effects of investigational drugs as victims or perpetrators of cypmediated drug interactions involving inhibition in the Simcyp simulator","author":"Yeo","year":"2022"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.120.000270","article-title":"Refined prediction of pharmacokinetic kratom-drug interactions: time-dependent inhibition considerations","volume":"376","author":"Tanna","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100122_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106884","article-title":"In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants","volume":"203","author":"Jin","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.dmd.2025.100122_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jps.2600630705","article-title":"Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol","volume":"63","author":"Garrett","year":"1974","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100122_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100135","article-title":"UGT2B7 mediated drug-drug interaction between cannabinoids and hydromorphone","author":"Coates","year":"2025","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.dmd.2025.100122_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112676","article-title":"A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults","volume":"272","author":"Zamarripa","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.dmd.2025.100122_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics16020243","article-title":"Cannabinoid-induced stereoselective inhibition of R-S-oxazepam glucuronidation: cannabinoid-oxazepam drug interactions","volume":"16","author":"Bardhi","year":"2024","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.dmd.2025.100122_bib37","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1124\/dmd.117.078055","article-title":"Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4\/5 and CYP3A7","volume":"45","author":"Kandel","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"19","key":"10.1016\/j.dmd.2025.100122_bib38","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/molecules28196900","article-title":"Differences of atomic-level interactions between midazolam and two CYP isoforms 3A4 and 3A5","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.dmd.2025.100122_bib39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0026-895X(24)12112-8","article-title":"Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation","volume":"61","author":"Khan","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100122_bib40","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1248\/cpb.52.830","article-title":"Characterization of the CYP3A4 active site by homology modeling","volume":"52","author":"Tanaka","year":"2004","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"10","key":"10.1016\/j.dmd.2025.100122_bib41","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1124\/dmd.108.022186","article-title":"Re-engineering of CYP2C9 to probe acid-base substrate selectivity","volume":"36","author":"Tai","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100122_bib42","first-page":"109","article-title":"Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography","volume":"320","author":"Crespi","year":"2006","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100122_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent p450 inhibition in human liver microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100122_bib44","first-page":"306","article-title":"Diclofenac versus indomethacin given as intravenous infusions: their effect on haemodynamics and bleeding time, and side-effects in healthy subjects","volume":"17","author":"Rorarius","year":"1985","journal-title":"Ann Clin Res"},{"issue":"12","key":"10.1016\/j.dmd.2025.100122_bib45","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1124\/dmd.108.022830","article-title":"CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver","volume":"36","author":"Inoue","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100122_bib46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2133\/dmpk.DMPK-11-RG-107","article-title":"Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity","volume":"27","author":"Yamaori","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2025.100122_bib47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0897190019854958","article-title":"Probable interaction between warfarin and inhaled and oral administration of cannabis","volume":"33","author":"Hsu","year":"2020","journal-title":"J Pharm Pract"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/bcpt.13152","article-title":"Interaction between warfarin and cannabis","volume":"124","author":"Damkier","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100122_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.gie.2024.01.013","article-title":"Marijuana and endoscopy: the effects of marijuana on sedation","volume":"100","author":"Kosirog","year":"2024","journal-title":"Gastrointest Endosc"},{"issue":"15","key":"10.1016\/j.dmd.2025.100122_bib50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.lfs.2006.12.032","article-title":"Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes","volume":"80","author":"Watanabe","year":"2007","journal-title":"Life Sci"},{"issue":"15","key":"10.1016\/j.dmd.2025.100122_bib51","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1111\/bph.15865","article-title":"Review of delta-8-tetrahydrocannabinol (Delta(8) -THC): comparative pharmacology with Delta(9)-THC","volume":"179","author":"Tagen","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100122_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cpt.3639","article-title":"Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction","volume":"118","author":"Ailabouni","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2025.100122_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/pharmaceutics16040447","article-title":"Impact of drug-mediated inhibition of intestinal transporters on nutrient and endogenous substrate disposition\u2026an afterthought?","volume":"16","author":"Kharve","year":"2024","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.dmd.2025.100122_bib54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.2012.167","article-title":"Drug trafficking: recent advances in therapeutics and disease","volume":"92","author":"Sprowl","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2025.100122_bib55","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/dmd.121.000623","article-title":"Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver","volume":"50","author":"Leeder","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib57","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.123.001384","article-title":"Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions","volume":"53","author":"Foti","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100122_bib58","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-025-55863-5","article-title":"Quantification and prediction of human fetal (-)-\u03949-THC\/(\u00b1)-11-OH-\u03949-THC exposure during pregnancy to inform fetal cannabis toxicity","volume":"16","author":"Kumar","year":"2025","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1016\/j.dmd.2025.100157","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:42:58Z","timestamp":1772800978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0090955625091317"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100122","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of \u03948-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100122"}}